Fractyl Health, Inc. (NASDAQ: GUTS)

Fractyl Health, Inc. is a clinical stage metabolic therapeutics company focused on developing novel approaches to treat obesity and type 2 diabetes. The company’s lead product candidate Revita is designed to remodel the duodenal lining via hydrothermal ablation using a balloon catheter in an outpatient procedure that typically lasts less than 45 minutes. Revita aims to reverse gut dysfunction caused by chronic high fat and high sugar diets which is a root cause of metabolic disease. Its second candidate Rejuva is a pancreas directed gene therapy platform that uses an adeno associated virus vector delivered through endoscopic ultrasound to restore endogenous production of metabolic hormones such as GLP1 and GIP. Rejuva is intended to provide durable metabolic benefit from a 1 administration by reprogramming pancreatic islet cells to secrete hormones in a nutrient responsive manner. Both programs seek to move treatment from chronic symptom management toward disease modification with the potential for durable benefit from a 1 intervention.

Fractyl Health, Inc. intends to generate revenue from the commercial sale of Revita and Rejuva after obtaining regulatory approval. The company has a letter of intent with Everself formerly Bariendo to support a scalable physician driven platform for product distribution. It is also working with CMS and private insurers to establish coverage and reimbursement for procedures using its product candidates. While the company has not yet launched any product it is investing in manufacturing capabilities and building a direct sales force to support a future United States launch. Revenue may also be derived from licensing agreements or collaborations that arise from its technology platform.

Fractyl Health, Inc. positions itself as a pioneer in disease modifying therapies that target the gut and pancreas addressing root causes of metabolic disease. Its main competitors include GLP1RA drug makers such as Novo Nordisk and Eli Lilly as well as providers of bariatric surgery and other device based therapies that rely on chronic dosing or invasive surgery. Competitive advantages stem from its focus on a 1 procedure that may provide durable effect without chronic dosing its Breakthrough Device designation for Revita and a growing patent portfolio that protects its technology. The company believes its approach offers a 1 in class opportunity to modify disease at the organ level rather than merely managing symptoms.

The company’s intended customers include patients with obesity or type 2 diabetes, physicians who perform endoscopic procedures, hospitals and ambulatory surgery centers, and health insurance payors. Fractyl Health, Inc. also plans to engage with gastroenterologists and endoscopic surgeons who will perform the procedures in clinical settings. It aims to provide hospitals with a new potentially profitable service line that can be integrated into existing endoscopy workflows. Payors are expected to benefit from reduced long term costs associated with obesity and type 2 diabetes management if the product candidates demonstrate durable clinical benefit.